LLY

883.98

+1.87%↑

UNH

498.24

+0.94%↑

NVO

142.49

-0.52%↓

JNJ

145.45

+0.05%↑

MRK

129.45

-0.61%↓

LLY

883.98

+1.87%↑

UNH

498.24

+0.94%↑

NVO

142.49

-0.52%↓

JNJ

145.45

+0.05%↑

MRK

129.45

-0.61%↓

LLY

883.98

+1.87%↑

UNH

498.24

+0.94%↑

NVO

142.49

-0.52%↓

JNJ

145.45

+0.05%↑

MRK

129.45

-0.61%↓

LLY

883.98

+1.87%↑

UNH

498.24

+0.94%↑

NVO

142.49

-0.52%↓

JNJ

145.45

+0.05%↑

MRK

129.45

-0.61%↓

LLY

883.98

+1.87%↑

UNH

498.24

+0.94%↑

NVO

142.49

-0.52%↓

JNJ

145.45

+0.05%↑

MRK

129.45

-0.61%↓

Search

ACADIA Pharmaceuticals Inc

Open

Branche Gesundheitswesen

15.15 -2.26

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

15.08

Max

15.58

Schlüsselkennzahlen

By Trading Economics

Einkommen

111M

46M

Verkäufe

-25M

206M

EPS

0.1

Gewinnspanne

19.822

Angestellte

597

EBITDA

93M

37M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+80.51 upside

Dividenden

By Dow Jones

Nächstes Ergebnis

31. Juli 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

16M

2.5B

Vorheriger Eröffnungskurs

17.41

Vorheriger Schlusskurs

15.15

Nachrichtenstimmung

By Acuity

43%

57%

95 / 370 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

ACADIA Pharmaceuticals Inc Chart

Ähnliche Nachrichten

12. Juni 2024, 20:51 UTC

Ergebnisse

Broadcom 2Q Sales Surge on AI, Cloud Demand

12. Juni 2024, 16:17 UTC

Ergebnisse
Wichtige Markttreiber

Autodesk Shares Rise 5% After 1Q Earnings, Revenue Beat Forecasts

12. Juni 2024, 23:36 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Broadcom in No Rush to Return to M&A -- Market Talk

12. Juni 2024, 23:08 UTC

Akquisitionen, Fusionen, Übernahmen

NHOA: TCC Group Holdings Plans to File a Simplified Tender Offer for NHOA Shrs, With a View to Delisting NHOA

12. Juni 2024, 22:56 UTC

Market Talk

Origin's Dividend May Not Grow as Fast as Bull Thought -- Market Talk

12. Juni 2024, 22:54 UTC

Market Talk

Mexico Pays $894M in Bonds to Help Next Administration -- Market Talk

12. Juni 2024, 21:16 UTC

Market Talk

Mexican Stocks Close Lower; Peso Loses More Ground -- Market Talk

12. Juni 2024, 20:56 UTC

Market Talk

Data Centers, AI to Drive Rising U.S. Power Demand -- Market Talk

12. Juni 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. Juni 2024, 20:34 UTC

Top News

S&P 500 Hits Fresh High After Cooler Inflation Data -- WSJ

12. Juni 2024, 20:32 UTC

Top News
Ergebnisse

Broadcom Sets 10-For-1 Stock Split and Posts Strong Earnings. The Stock Is Rising. -- Barrons.com

12. Juni 2024, 20:29 UTC

Market Talk

Bank of Mexico May Intervene to Address Peso Volatility

12. Juni 2024, 20:17 UTC

Ergebnisse

Broadcom Sees FY24 Adj EBITDA About 61 % of Projected Rev >AVGO

12. Juni 2024, 20:17 UTC

Ergebnisse

Broadcom: Trading on Split-Adjusted Basis Expected to Commence July 15 >AVGO

12. Juni 2024, 20:16 UTC

Ergebnisse

Broadcom Announces Ten-for-one Forward Stk Split >AVGO

12. Juni 2024, 20:16 UTC

Ergebnisse

Broadcom Sees FY24 Rev $51B, Including Contribution From VMware >AVGO

12. Juni 2024, 20:15 UTC

Ergebnisse

Broadcom 2Q Net $2.12B >AVGO

12. Juni 2024, 20:15 UTC

Ergebnisse

Broadcom 2Q EPS $4.42 >AVGO

12. Juni 2024, 20:15 UTC

Ergebnisse

Broadcom 2Q Adj EPS $10.96 >AVGO

12. Juni 2024, 20:15 UTC

Ergebnisse

Broadcom 2Q Rev $12.49B >AVGO

12. Juni 2024, 19:00 UTC

Top News

New York City Traffic Is Horrendous. There's No Relief in Sight. -- WSJ

12. Juni 2024, 18:58 UTC

Market Talk

Oil Shakes Off U.S. Stock Build, Bearish IEA, Hawkish Fed -- Market Talk

12. Juni 2024, 18:51 UTC

Market Talk

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

12. Juni 2024, 18:50 UTC

Market Talk

Gold Pares Gains Following Fed Rate Decision -- Market Talk

12. Juni 2024, 18:18 UTC

Market Talk

Fed Cuts Projection for Interest Rate Cuts -- Market Talk

12. Juni 2024, 18:12 UTC

Market Talk

Treasury Yields Tick Higher As Fed Holds Rates, Increases Inflation Projection -- Market Talk

12. Juni 2024, 18:11 UTC

Top News

Canada Fights for Economic Security in Pre-Election U.S. Campaign -- Talking Markets

12. Juni 2024, 18:02 UTC

Market Talk

Market Talk Roundup: USDA Foreign Grain Forecasts Seen Conservative

12. Juni 2024, 16:37 UTC

Market Talk

More U.S. Homes Staying on the Market Longer -- Market Talk

12. Juni 2024, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

Peer-Vergleich

Kursveränderung

ACADIA Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

80.51% Vorteil

12-Monats-Prognose

Durchschnitt 27.13 USD  80.51%

Hoch 39 USD

Tief 17 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ACADIA Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

15 ratings

11

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

14.86 / 15.28Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

95 / 370 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

$

Über ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).